Drug Trial Radar · NCT04225598
Emergency Department-Initiated Buprenorphine Validation Network Trial
Last checked: Nov 19, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Actual
Start
Jul 8, 2020
Primary completion
Dec 6, 2024
Study completion Dec 6, 2024
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Drug Abuse Treatment Clinical Trials Network; The Emmes Company, LLC; Harvard Medical School (HMS and HSDM); University of Pennsylvania; NYU Langone Health; Icahn School of Medicine at Mount Sinai; Alameda Health System; Weill Medical College of Cornell University; National Institute on Drug Abuse (NIDA)
- First posted
- Jan 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will (1) recruit, train and provide resources to approximately 30 Emergency Department (ED) sites throughout the U.S. using implementation facilitation strategies to provide ED-initiated buprenorphine (BUP) for patients presenting with opioid use disorder (OUD) who are not receiving medications for opioid use disorder (MOUD). Once implementation is adequately achieved, the sites will (2) conduct a randomized controlled trial (RCT) to compare the effectiveness of sublingual buprenorphine (SL-BUP) versus extended-release buprenorphine (XR-BUP) on ED patients' engagement in formal addiction treatment 7-days after their ED visit. In addition, in an ancillary component of the study, the investigators will (3) assess the use of XR-BUP in ED patients with Clinical Opioid Withdrawal Scale (COWS) scores \< 8 in a case series to potentially expand the eligibility of patients in the larger RCT to those presenting with little to no opioid withdrawal symptoms. Finally, the investigators will (4) develop and validate ED electronic health record (EHR) opioid-related phenotypes, both of which will inform the main RCT.
Conditions
- Opioid-use Disorder
Interventions
CAM2038Drug
Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
Buprenorphine Sublingual ProductDrug
COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS \>≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder). COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RCT Component: Patient engagement (yes/no) in formal addiction treatment at 7 days post randomizationTime frame: 7 days post randomization
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Highland Hospital
Oakland, California
San Leandro Hospital
San Leandro, California
Yale New Haven Health (Yale New Haven Hospital)
New Haven, Connecticut
Jackson Memorial Hospital
Miami, Florida
Tampa General Hospital
Tampa, Florida
Grady Memorial Hospital
Atlanta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
University of Chicago Medicine
Chicago, Illinois
Maine Medical Center
Portland, Maine
Johns Hopkins Hospital
Baltimore, Maryland
Detroit Receiving Hospital
Detroit, Michigan
Henry Ford Hospital
Detroit, Michigan
Hennepin County Medical Center
Minneapolis, Minnesota
Barnes Jewish Hospital
St Louis, Missouri
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Cooper University Hospital
Camden, New Jersey
Presybterian Hospital, Albuquerque, NM
Albuquerque, New Mexico
University of New Mexico Hospital
Albuquerque, New Mexico
Bellevue Hospital
New York, New York
Icahn School of Medicine
New York, New York
Columbia University Irving Medical Center- NY Presbyterian
New York, New York
Weill Cornell Medical College
New York, New York
Upstate Medical University
Syracuse, New York
Duke University
Durham, North Carolina
Wake Forest School of Medicine
Winston-Salem, North Carolina
Pennsylvania Presbyterian Medical Center/Hospital of UPENN
Philadelphia, Pennsylvania
Temple University Hospital - Episcopal Campus
Philadelphia, Pennsylvania
UPMC Mercy Hospital
Pittsburgh, Pennsylvania
Rhode Island Hospital/The Miriam Hospital
Providence, Rhode Island
Medical University of South Carolina
Charleston, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Parkland Memorial Hospital
Dallas, Texas
University of Utah Hospital
Salt Lake City, Utah
University of Washington Medical Center- Harborview/Montlake
Seattle, Washington
West Virginia University - Berkeley Medical Center
Martinsburg, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.